Movement Alert｜Abivax S.A. Intraday Rise 5.2% in Regular Trading, Focus Remains on Pipeline Value After Target Price Cut

Market Focus10-20

On October 20, Abivax S.A. rose 5.2% in Regular Trading, trading near $92.0, with turnover of $56.811 million.

The clearest recent catalyst is an event-driven analyst action: Wedbush lowered its price target on Abivax S.A. to $96 from $118 while maintaining a Neutral rating, even as the stock moved higher intraday.

Background context shows this follows earlier estimate cuts after the company reported H1 EPS of $(2.43), worse than the $(1.08) consensus, while sales of $2.959 million topped the $1.860 million estimate. Market attention remains centered on obefazimod, the company’s lead Phase 3 candidate for moderately to severely active ulcerative colitis, with investors continuing to watch regulatory filing progress and commercialization prospects.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment